Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.
New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu 41061, Republic of Korea.
Mol Microbiol. 2018 Jun;108(5):567-577. doi: 10.1111/mmi.13950. Epub 2018 Mar 30.
Originally annotated as the initiator of fatty acid synthesis (FAS), β-ketoacyl-acyl carrier protein synthase III (KAS III) is a unique component of the bacterial FAS system. Novel variants of KAS III have been identified that promote the de novo use of additional extracellular fatty acids by FAS. These KAS III variants prefer longer acyl-groups, notably octanoyl-CoA. Acinetobacter baumannii, a clinically important nosocomial pathogen, contains such a multifunctional KAS III (AbKAS III). To characterize the structural basis of its substrate specificity, we determined the crystal structures of AbKAS III in the presence of different substrates. The acyl-group binding cavity of AbKAS III and co-crystal structure of AbKAS III and octanoyl-CoA confirmed that the cavity can accommodate acyl groups with longer alkyl chains. Interestingly, Cys264 formed a disulfide bond with residual CoA used in the crystallization, which distorted helices at the putative interface with acyl-carrier proteins. The crystal structure of KAS III in the alternate conformation can also be utilized for designing novel antibiotics.
最初被注释为脂肪酸合成(FAS)的启动子,β-酮酰-酰基载体蛋白合酶 III(KAS III)是细菌 FAS 系统的独特组成部分。已经鉴定出了促进 FAS 新利用额外的细胞外脂肪酸的新型 KAS III 变体。这些 KAS III 变体更喜欢长酰基,特别是辛酰基辅酶 A。鲍曼不动杆菌是一种重要的临床医院病原体,含有这种多功能 KAS III(AbKAS III)。为了表征其底物特异性的结构基础,我们在存在不同底物的情况下确定了 AbKAS III 的晶体结构。AbKAS III 的酰基结合腔和 AbKAS III 与辛酰基辅酶 A 的共晶体结构证实了该腔可以容纳具有更长烷基链的酰基。有趣的是,Cys264 与用于结晶的残留 CoA 形成了二硫键,这扭曲了与酰基载体蛋白假定界面的螺旋。KAS III 的交替构象的晶体结构也可用于设计新型抗生素。